COMIRB: 21-3149
Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Study with a Long-term Open-label Extension
Principal Investigator: Ara Metjian
Eligibility: Ages ≥ 18; Diagnosed with warm autoimmune hemolytic anemia (wAIHA) for at least 3 months; must be able to understand and voluntarily provide written informed consent
ClinicalTrials.gov Identifier: NCT04119050